Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Stefano Luzi Fedeli
A Phase II Study of Modified FOLFOX as First-Line Chemotherapy for Metastatic Gastric Cancer in Elderly Patients With Associated Diseases
Gastric Cancer
Cancer Research
Medicine
Oncology
Gastroenterology
HtrA1, a Potential Predictor of Response to Cisplatin-Based Combination Chemotherapy in Gastric Cancer
Histopathology
Medicine
Forensic Medicine
Pathology
Histology
Related publications
Oxaliplatin, 5-Fluorouracil and Leucovorin (Modified FOLFOX-6) as First-Line Chemotherapy for Advanced Gastric Cancer Patients With Poor Performance Status
Oncology Letters
Cancer Research
Oncology
FOLFOX as Second-Line Chemotherapy in Patients With Pretreated Metastatic Pancreatic Cancer From the FIRGEM Study
BMC Cancer
Cancer Research
Oncology
Genetics
Phase II Trial of Palbociclib in Patients With Metastatic Urothelial Cancer After Failure of First-Line Chemotherapy
British Journal of Cancer
Cancer Research
Oncology
Capecitabine and Irinotecan as First- Line Chemotherapy for Patients With Metastatic Colorectal Cancer
Journal of IMAB - Annual Proceeding (Scientific Papers)
Dentistry
A Multi-Center Phase II Study and Biomarker Analysis of Combined Cetuximab and Modified FOLFIRI as Second-Line Treatment in Patients With Metastatic Gastric Cancer
BMC Cancer
Cancer Research
Oncology
Genetics
Effects of Modified FOLFOX-6 Chemotherapy on Cellular Immune Function in Patients With Gastric Cancer
Oncology Letters
Cancer Research
Oncology
Pemetrexed for Previously Treated Patients With Metastatic Gastric Cancer: A Prospective Phase II Study
British Journal of Cancer
Cancer Research
Oncology
A Multicenter Clinical Phase II Study of FOLFOXIRI Plus Bevacizumab as First-Line Therapy in Patients With Metastatic Colorectal Cancer: QUATTRO Study
Clinical Colorectal Cancer
Oncology
Gastroenterology
First-Line Single-Agent Chemotherapy for Patients With Recurrent or Metastatic Gastric Cancer With Poor Performance Status
Experimental and Therapeutic Medicine
Medicine
Cancer Research
Immunology
Microbiology
